The prevalence of chronic diseases combined with their sky-high price tags is drawing interest to digital therapeutics (DTx), a new class of medicine that relies on software programs to prevent, manage, and treat diseases. The fact that Big Pharma and Insurers now want in on the action is the latest sign that the DTx market is on the cusp of rapid growth and should be on every health care investor’s radar.
To read this Market Insight, you’ll need to sign in
If you don’t have a subscription, get in touch for a free trial.
